These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12945008)

  • 1. High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C.
    Moskovitz DN; Manoharan P; Heathcote EJ
    Can J Gastroenterol; 2003 Aug; 17(8):479-82. PubMed ID: 12945008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
    Keeffe EB; Hollinger FB
    Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group.
    Jensen DM; Krawitt EL; Keeffe EB; Hollinger FB; James SP; Mullen K; Everson GT; Hoefs JC; Fromm H; Black M; Foust RT; Pimstone NR; Heathcote EJ; Albert D
    Am J Gastroenterol; 1999 Dec; 94(12):3583-8. PubMed ID: 10606323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
    Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.
    Poynard T; Colombo M; Bruix J; Schiff E; Terg R; Flamm S; Moreno-Otero R; Carrilho F; Schmidt W; Berg T; McGarrity T; Heathcote EJ; Gonçales F; Diago M; Craxi A; Silva M; Bedossa P; Mukhopadhyay P; Griffel L; Burroughs M; Brass C; Albrecht J;
    Gastroenterology; 2009 May; 136(5):1618-28.e2. PubMed ID: 19208349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study.
    da Silva LC; Bassit L; Ono-Nita SK; Pinho JR; Nishiya A; Madruga CL; Carrilho FJ
    J Gastroenterol; 2002; 37(9):732-6. PubMed ID: 12375147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone.
    Min AD; Jones JL; Esposito S; Lebovics E; Jacobson IM; Klion FM; Goldman IS; Geders JM; Tobias H; Bodian C; Bodenheimer HC
    Am J Gastroenterol; 2001 Apr; 96(4):1143-9. PubMed ID: 11316161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
    Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX
    J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study.
    Barbaro G; Barbarini G
    Eur J Gastroenterol Hepatol; 2002 May; 14(5):477-83. PubMed ID: 11984144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
    Reichard O; Norkrans G; Frydén A; Braconier JH; Sönnerborg A; Weiland O
    Lancet; 1998 Jan; 351(9096):83-7. PubMed ID: 9439491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.
    Teuber G; Berg T; Hoffmann RM; Leifeld L; Lafrenz M; Spengler U; Pape GR; Hopf U; Zeuzem S
    Digestion; 2000; 61(2):90-7. PubMed ID: 10705172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High sustained response to daily dosing of interferon with ribavirin in chronic hepatitis C patients naïve to therapy.
    Abbas Z; Hamid S; Tabassum S
    J Gastroenterol Hepatol; 2002 May; 17(5):577-81. PubMed ID: 12084032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early prediction of nonresponders to treatment with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Liu LW; Tomlinson G; Mazzulli T; Murray A; Heathcote J
    Can J Gastroenterol; 2003 Aug; 17(8):483-7. PubMed ID: 12945009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
    de Lédinghen V; Trimoulet P; Winnock M; Bernard PH; Bourlière M; Portal I; Rémy AJ; Szostak N; Lévy S; Tran A; Abergel A; Chêne G; Fleury H; Couzigou P;
    J Hepatol; 2002 Jun; 36(6):819-26. PubMed ID: 12044534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
    Bacon BR; Shiffman ML; Mendes F; Ghalib R; Hassanein T; Morelli G; Joshi S; Rothstein K; Kwo P; Gitlin N
    Hepatology; 2009 Jun; 49(6):1838-46. PubMed ID: 19291790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3].
    Cornberg M; Hüppe D; Wiegand J; Felten G; Wedemeyer H; Manns MP
    Z Gastroenterol; 2003 Jun; 41(6):517-22. PubMed ID: 12806536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
    Berg T; Kaul T; Naumann U; Wiedenmann B; Hopf U
    Z Gastroenterol; 2000 Nov; 38(11):881-6. PubMed ID: 11132533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial.
    Alaimo G; Di Marco V; Ferraro D; Di Stefano R; Porrovecchio S; D'Angelo F; Calvaruso V; Craxì A; Almasio PL
    World J Gastroenterol; 2006 Nov; 12(42):6861-4. PubMed ID: 17106937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
    Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
    Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.